

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan (MHRA-100392-PIP01-21-M03) and to the deferral

MHRA-100392-PIP01-21-M04

### **Scope of the Application**

#### **Active Substance(s)**

Highly purified single-stranded, 5'-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2); TOZINAMERAN; FAMTOZINAMERAN

#### **Condition(s)**

Prevention of coronavirus disease 2019 (COVID-19)

#### **Pharmaceutical Form(s)**

Concentrate for dispersion for injection Dispersion for injection

#### **Route(s) of Administration**

INTRAMUSCULAR USE

#### **Name / Corporate name of the PIP applicant**

BioNTech Manufacturing GmbH

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, BioNTech Manufacturing GmbH submitted to the licensing authority on 10/10/2023 16:14 BST an application for a Modification

The procedure started on 16/01/2024 07:28 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100392-PIP01-21-M04

Of 04/03/2024 16:06 GMT

On the adopted decision for Highly purified single-stranded, 5'-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2); TOZINAMERAN; FAMTOZINAMERAN (MHRA-100392-PIP01-21-M04) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for Highly purified single-stranded, 5'-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2); TOZINAMERAN; FAMTOZINAMERAN, Concentrate for dispersion for injection; Dispersion for injection , INTRAMUSCULAR USE .

This decision is addressed to BioNTech Manufacturing GmbH, An der Goldgrube 12, Mainz, GERMANY, 55131

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Not applicable
----------------

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Prevention of Coronavirus disease 2019 (COVID-19)
---

## 2.2 Indication(s) targeted by the PIP:

Prevention of Coronavirus disease 2019 (COVID-19)

## 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age

## 2.4 Pharmaceutical Form(s):

Concentrate for dispersion for injection Dispersion for injection

## 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	6	Study 1 (C4591001) Double blind, dose-finding study of safety, tolerability and immunogenicity of 2 different SARS-CoV-2 vaccine candidates (adults only) (part 1) and placebo-controlled efficacy, safety and immunogenicity study of highly purified single-stranded, 5'-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2) in adolescents from 12 years to less than 18 years of age (and adults) (part 2) for prevention of COVID-19. Study 2 (C4591007) Double blind, controlled, dose-finding safety, tolerability and immunogenicity study of tozinameran in paediatric subjects from 6 months to less than 16 years of age for prevention of COVID-19. Study 3 Open label, controlled, dose-finding, safety and immunogenicity study of tozinameran in children from birth to less than 6 months of age for prevention of COVID-19. Study 4 (C4591024) Open label, uncontrolled, safety and immunogenicity study of tozinameran in immunocompromised children from birth to less than 18 years of age for prevention of

		<p>COVID-19. Study 5 (C4591044)  Added during procedure  MHRA-100392-PIP01-21-M03.  Open label, safety, tolerability  and immunogenicity study of  a booster dose of tozinameran/  famtozinameran in adolescents  from 12 years to less than 18  years of age (and adults) for the  prevention of COVID-19. Study 6  (C4591048) Added during procedure  MHRA-100392-PIP01-21-M03.  Observer-blind, randomised,  controlled, safety, tolerability  and immunogenicity study of a  primary series of tozinameran/  famtozinameran in children from 6  months to less than 4 years and 3  months of age (sub study A: SSA),  and open label, safety, tolerability  and immunogenicity study of  a booster dose of tozinameran/  famtozinameran in children from 6  months to less than 12 years age for  the prevention of COVID-19 (Sub  studies B, C, and D).</p>
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	0	Not applicable.
<b>Other Studies</b>	0	Not applicable.
<b>Other Measures</b>	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	No
<b>Date of completion of the paediatric investigation plan:</b>	30/11/2025
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes

